Performance has declined for three consecutive

[shapanwwuopi]

Host: Still very small. right. I mean, it's just that the lenses are thicker.

Mark Zuckerberg: Yeah, and I think we want to make it a little bit smaller. We also need to reduce costs significantly. Currently, each pair of glasses costs more than $10,000 to manufacture, which is impossible to make a successful consumer product. So we have to miniaturize further.

But, I mean, what we put in there is actually the equivalent of a supercomputer from 10 or 20 years ago, plus lasers in the temples, and nano-etching on the lenses so that they can see the image, and microphones and speakers, and Wi-Fi for connecting to other devices. It's crazy how much technology can be miniaturized into something this small. We have been working on this project for 10 years. This is really interesting.

But yeah, I think in it, the glasses, all the AI ​​stuff.

Before this merger and acquisition , Shengxiang Bio 's attributable net profit had declined for three consecutive years from.

In the first three quarters of 2024, Shengxiang Bio's attributable chinese student data net profit also declined. During the reporting period, the company achieved operating income of 1.033 billion yuan, a year-on-year increase of 63.24%; the corresponding attributable net profit was 195 million yuan, a year-on-year decrease of 34.8%.


In order to reduce its dependence on the sales of new coronavirus nucleic acid testing reagents and instruments , in 2022, Shengxiang Bio proposed "second entrepreneurship" to find new growth points.

On May 9, 2023, the company announced that it plans to jointly invest with its related parties to establish Hunan Shengxiang Ansai Biotechnology Co., Ltd. to further improve the company's comprehensive strategic layout in the field of immunodiagnosis, especially chemiluminescence.

A year later, Shengxiang Bio announced again that it plans to jointly invest with its related parties in a joint venture, Hunan Shengwei Sumin Biotechnology Co., Ltd., to further focus on the field of rapid drug sensitivity testing.